Kaplan + Sadock's Synopsis of Psychiatry, 11e

1064

Chapter 29: Psychopharmacological Treatment

1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36(6):843–854. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012; 367(17):1577–1579. Garvey WT. New tools for weight-loss therapy enable a more robust medical model for obesity treatment: Rationale for a complications-centric approach. Endocr Pract. 2013;19(5):864–874. Hampl JS, Lehmann J, Fielder EG. How United States newspapers framed weight- loss drugs. J Acad Nutr Diet. 2013;113(9):A20. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwar-

zenberg SJ. Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study. Obesity. 2012;20(2):364–370. O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Brian Raether, Anderson CM, Shanahan WR. Randomized placebo-controlled clini- cal trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM- DM study. Obesity. 2012;20(7):1426–1436. Suplicy H, Boguszewski CL, dos Santos CMC, de Figueiredo MD, Cunha DR, Radominski R. A comparative study of five centrally acting drugs on the phar- macological treatment of obesity. Int J Obes. 2014:1–7. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon- like peptide-1 receptor agonists on weight loss: Systematic review and meta- analyses of randomised controlled trials. BMJ. 2012;344.